| Search by tag or site | Login to my blog ? Start my own blog |
 |
BioHealth InvestorBioHealth Investor (BHI) is a blog and journal focused on providing updated commentary and financial news from the biotech and medical technology industry. BHI's content is featured on Yahoo!Finance, Google Finance, TheStreet.com, SeekingAlpha.com and many other blogs and websites. BHI is also a proud member of The Business of Biotech Network, and the Investors Blog Network. |
Biotech Earnings Into Full Swing Thursday
Posted on 07/19/2007 12:02:56 | Link | Post Comment
by Brett Scott
Sizz's Biotech Blog
Genentech (DNA) started the biotech earnings season on a mixed note last Thursday as second quarter earnings beat the Street's estimates, but its outlook was less than stellar. Biotech might take a backseat to tech bellwethers Microsoft (MSFT) and Google (GOOG) Thursday, but big biotech Gilead reports Thursday and other big biotechs Amylin, Biogen, Genzyme, Celgene and Amgen report next week.
Here is what the Street is expecting from biotech's second quarter.
Gilead (GILD): EPS: $0.39 (39% growth), Revenues: $1.02B (49% growth)
Amylin (AMLN): EPS: $-0.34 (10%), Revenues: $198M (67%)
Biogen (BIIB): EPS: $0.63 (11%), Revenues: $759M (15%)
Genzyme (GENZ): EPS: $0.81 (19%), Revenues: $912M (15%)
Celgene (CELG): EPS: $0.23 (109%), Revenues: $318M (61%)
Amgen (AMGN): EPS: $1.06 (1%), Revenues: $3.69B (2%)
RELATED READING:
- Why Biotech and Not Big Pharma
- The Risks of Small Biotech
- Valuing Biotechs
- Short Squeezing Biotechs
- Strategy for Investing in Small Biotechs
- The Biotech Industry: 30 Years of Failure
Sizz's Biotech Blog is a regular contributor to BioHealth Investor
___________________
Sizz's Biotech Blog
Genentech (DNA) started the biotech earnings season on a mixed note last Thursday as second quarter earnings beat the Street's estimates, but its outlook was less than stellar. Biotech might take a backseat to tech bellwethers Microsoft (MSFT) and Google (GOOG) Thursday, but big biotech Gilead reports Thursday and other big biotechs Amylin, Biogen, Genzyme, Celgene and Amgen report next week.
Here is what the Street is expecting from biotech's second quarter.
Gilead (GILD): EPS: $0.39 (39% growth), Revenues: $1.02B (49% growth)
Amylin (AMLN): EPS: $-0.34 (10%), Revenues: $198M (67%)
Biogen (BIIB): EPS: $0.63 (11%), Revenues: $759M (15%)
Genzyme (GENZ): EPS: $0.81 (19%), Revenues: $912M (15%)
Celgene (CELG): EPS: $0.23 (109%), Revenues: $318M (61%)
Amgen (AMGN): EPS: $1.06 (1%), Revenues: $3.69B (2%)
RELATED READING:
- Why Biotech and Not Big Pharma
- The Risks of Small Biotech
- Valuing Biotechs
- Short Squeezing Biotechs
- Strategy for Investing in Small Biotechs
- The Biotech Industry: 30 Years of Failure
Sizz's Biotech Blog is a regular contributor to BioHealth Investor
___________________
- Mri To Lead Growth In Medical-imaging Market
- Malaria And Hiv - Eradication And Treatment
- Dragon’s New Production Process To Cut Costs
- Mrsa Update: Cepheid, Basilea And Nektar
- If Only Us Health Care Could Be More Like The Patriots (or Even The Red Sox) And Less Like The Yankees
- The Technical Trader
- Wishing Wealth
- Financial Skeptic
- Don't Mess With Taxes
- Poor and Stupid
- Commodity Option Selling
Examples
ATM Wallstreet - Mon Oct 06, 2008 03:39PM
Made several great trades today. Traded the QID, QQ [read more]
Made several great trades today. Traded the QID, QQ [read more]
ATM Wallstreet - Sat Oct 04, 2008 10:41PM
When I first started Day Trading I traded anything that [read more]
When I first started Day Trading I traded anything that [read more]
ATM Wallstreet - Tue Oct 07, 2008 10:07PM
Today we have the Fed speaking and release of Fed mi [read more]
Today we have the Fed speaking and release of Fed mi [read more]
<< My Home | TheMoneyBlogs Home